diclofenac has been researched along with Heart Failure in 15 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a multivariate analysis of 34 701 patients with arthritis receiving etoricoxib 60 or 90 mg, or diclofenac 150 mg, daily for a mean of 18 months, to assess the incidence of confirmed, adjudicated CHF events resulting in emergency room visit or hospitalization." | 9.14 | Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Wang, H; Weir, MR, 2009) |
| "Non-steroidal anti-inflammatory drugs (NSAID) or high doses of aspirin (acetylsalicylic acid) can exert detrimental effects on renal function and counteract the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure." | 9.11 | Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. ( Björkman, S; Fyge, A; Gunnarsson, B; Höglund, P; Juhlin, T; Roth, B, 2004) |
| "We evaluated the relationship between baseline BP and change in BP on CV events (CVEs) in patients receiving NSAIDs or COX-2 inhibitors in the prospective randomized, double-blind, Multinational Etoricoxib and Diclofenac Arthritis Long-term Program (N = 34,701) comparing etoricoxib 60 or 90 mg or diclofenac 150 mg daily for a mean duration of 18 months." | 5.16 | Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. ( Brater, DC; Cannon, CP; Curtis, SP; Gammaitoni, A; Kaur, A; Krum, H; Laine, L; Peloso, PM; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2012) |
| "We performed a multivariate analysis of 34 701 patients with arthritis receiving etoricoxib 60 or 90 mg, or diclofenac 150 mg, daily for a mean of 18 months, to assess the incidence of confirmed, adjudicated CHF events resulting in emergency room visit or hospitalization." | 5.14 | Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Wang, H; Weir, MR, 2009) |
| "Non-steroidal anti-inflammatory drugs (NSAID) or high doses of aspirin (acetylsalicylic acid) can exert detrimental effects on renal function and counteract the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure." | 5.11 | Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. ( Björkman, S; Fyge, A; Gunnarsson, B; Höglund, P; Juhlin, T; Roth, B, 2004) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "A 40-year-old male with Becker muscular dystrophy and cardiac involvement was stable in New York Heart Association class II for 7 years." | 1.33 | Worsening of heart failure in Becker muscular dystrophy after nonsteroidal anti-inflammatory drugs. ( Finsterer, J; Stöllberger, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, M | 2 |
| Hallas, J | 1 |
| Ernst, MT | 1 |
| Pottegård, A | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Nadesalingam, K | 1 |
| Kirby, D | 1 |
| Fosbøl, EL | 1 |
| Torp-Pedersen, C | 1 |
| Olsen, AS | 1 |
| Christensen, B | 1 |
| Gislason, GH | 1 |
| Harris, D | 1 |
| Pease, N | 1 |
| Krum, H | 2 |
| Curtis, SP | 3 |
| Kaur, A | 3 |
| Wang, H | 2 |
| Smugar, SS | 2 |
| Weir, MR | 2 |
| Laine, L | 3 |
| Brater, DC | 2 |
| Cannon, CP | 3 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Brune, K | 1 |
| Swergold, G | 1 |
| Gammaitoni, A | 1 |
| Peloso, PM | 1 |
| van der Heijden, PG | 1 |
| van Puijenbroek, EP | 1 |
| van Buuren, S | 1 |
| van der Hofstede, JW | 1 |
| Juhlin, T | 2 |
| Björkman, S | 1 |
| Gunnarsson, B | 1 |
| Fyge, A | 1 |
| Roth, B | 1 |
| Höglund, P | 2 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Erhardt, LR | 1 |
| Ottosson, H | 1 |
| Jönsson, BA | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Van den Ouweland, FA | 1 |
| Gribnau, FW | 1 |
| Meyboom, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for diclofenac and Heart Failure
| Article | Year |
|---|---|
[Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Blood Pressure; Cardiovascular Disease | 2016 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
4 trials available for diclofenac and Heart Failure
| Article | Year |
|---|---|
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Body Weight; Comorbidity; | 2012 |
Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cr | 2004 |
Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2007 |
9 other studies available for diclofenac and Heart Failure
| Article | Year |
|---|---|
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart | 2023 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Cardiovascular safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebrovascular Disorders; Contraindications; Diclofenac; D | 2013 |
Anti-inflammatories and heart failure-identifying patients at risk.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents; Chondrosarcoma; Diclofenac; Heart Failure; Humans; Mal | 2009 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2002 |
Worsening of heart failure in Becker muscular dystrophy after nonsteroidal anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Heart Failure; Humans; Male; Muscular Dy | 2005 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Heart Failure; | 1988 |